Negative impact of sedation on esophagogastric junction evaluation during esophagogastroduodenoscopy

Table 5 Univariate analysis of factors associated with non-excellent observation of esophagogastric junction territory

	Excellent	Non-excellent	P value
	(n = 51)	(n = 52)
Age, yr	59.39 ± 9.5	57.5 ± 11.1	0.355
Male	11 (21.6)	23 (44.2)	0.377
Weight, kg	61.29 ± 8.8	63.05 ± 11.5	0.384
Height, cm	161.29 ± 7.7	161.37 ± 9.6	0.706
BMI	23.33 ± 2.8	24.10 ± 3.1	0.185
Abdomen, cm	82.97 ± 9.5	85.27 ± 9.4	0.221
Hip, cm	92.98 ± 5.5	95.14 ± 6.5	0.073
HW ratio	0.89 ± 0.06	0.89 ± 0.05	0.704
Comorbidity
Hypertension	11 (21.6)	15 (28.8)	0.395
Diabetes mellitus	4 (7.8)	11 (21.2)	0.057
Cardiovascular accident	2 (3.9)	1 (1.9)	0.548
Ischemic heart disease	2 (3.9)	3 (5.8)	0.664
Liver disease	2 (3.9)	3 (5.8)	0.664
Sedation			< 0.001
No	32 (62.7)	3 (5.8)
Midazolam	10 (19.6)	25 (48.1)
Propofol	9 (17.6)	24 (43.2)

Data are expressed as absolute numbers (percentage) or mean ± SD. BMI: Body mass index.